Line of abiraterone acetate in castration-resistant metastatic prostate cancer--Does it matter? report of a multi-institutional experience.

Abstract

OBJECTIVE:

We present our data comparing retrospectively the efficacy of abiraterone and cabazitaxel in patients who progress after docetaxel treatment.

PATIENTS AND METHODS:

The study included 56 patients diagnosed with hormone-refractory metastatic prostate cancer who were previously treated with abiraterone therapy at four oncology centers in Turkey.

RESULTS:

With abiraterone, the patients had a median progression-free survival (PFS) of 5.9 months (95% confidence interval (CI) for hazard ratio (HR) (4.4-7.4)) and an overall survival of 13.4 months (95% CI for HR (5.5-21.3)). When we compared the disease-free survival (DFS) of reference patients treated with cabazitaxel as a second-line treatment with those receiving second-line abiraterone therapy, there was no significant difference. (PFS = 5.9 months with cabazitaxel vs. 6.7 months with abiraterone, P = 0.213).

CONCLUSION:

This study has shown that in our experience abiraterone acetate is an effective agent in metastatic castration-resistant prostate cancer (mCRPC) regardless of the line of treatment.

• Authors: S Gunduz, H Bozcuk, M Yıldız, S S Goksu, M Uysal, D Arslan, A M Tatlı, H Mutlu, H S Coşkun, M Ozdogan
• Journal: Indian journal of cancer (Indian J Cancer) 2015 Oct-Dec Vol. 52 Issue 4 Pg. 658-60 ISSN: 1998-4774 [Electronic] India
• PMID: 26960509 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Androstenes
• abiraterone

Topics

• Aged
• Aged, 80 and over
• Androstenes (therapeutic use)
• Disease-Free Survival
• Humans
• Male
• Middle Aged
• Prostatic Neoplasms, Castration-Resistant (drug therapy, mortality)
• Retrospective Studies
• Treatment Outcome